Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study-Reference-Cited by-同舟云学术

Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study

Published:2021-01 Issue:1 Volume:8 Page:103-105
ISSN:2347-5625
Container-title:Asia-Pacific Journal of Oncology Nursing
language:en
Short-container-title:Asia-Pacific Journal of Oncology Nursing

Author:

Barber Fedricker D

Publisher

Elsevier BV

Subject

Oncology (nursing),Oncology

Reference10 articles.

1. West H, Dahlberg S. Clinical trials, end points, and statistics-measuring and comparing cancer treatments in practice. JAMA Oncol 1798.

2. Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL. Cancer immunotherapy trials: Leading a paradigm shift in drug development. J Immunother Cancer 42.

3. Myers G. Immune-related adverse events of immune checkpoint inhibitors: A brief review. Curr Oncol 342–7.

4. Kim D. Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer. Clin Case Rep 935–8.

5. Pilato F, Distefano M, Calandrelli R. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: Clinical and radiological considerations. Front Neurol 34.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation and management of acute high-grade immunotherapy-related neurotoxicity;Heliyon;2023-03

2. Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions;Frontiers in Ophthalmology;2022-11-18

3. Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung Cancer;Diagnostics;2022-06-02

4. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice;Neurological Sciences;2022-02-17

5. Evaluation and Management of Acute High-Grade Immunotherapy-Related Neurotoxicity;SSRN Electronic Journal;2022